Akèy › Sistèm Imunitè ak Twoub › Massachusetts › Boston
Etid klinik pou Sistèm Imunitè ak Twoub nan Boston, MA
10 etid pou Sistèm Imunitè ak Twoub ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- Beth Israel Deaconess Medical Center - Research, Boston
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Ap rekriteFaz 3
- Massachusetts General Hospital, Boston
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
Ap rekriteEtid obsèvasyon
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Ap rekriteFaz 2
- Dana-Farber Cancer Institute, Boston
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Ap rekriteFaz 3
- Massachusetts General Hospital, Boston
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Ap rekriteFaz 1/2
- Brigham and Women's Hospital, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
Ap rekriteFaz 2
- Dana-Farber Cancer Institute, Boston
Etid Sistèm Imunitè ak Twoub nan lòt vil
- Washington, DC13 etid
- New York City, NY12 etid
- Philadelphia, PA10 etid
- Portland, OR9 etid
- Atlanta, GA9 etid
- Houston, TX9 etid
- Chicago, IL8 etid
- Los Angeles, CA8 etid
- Cleveland, OH8 etid
- Seattle, WA6 etid
- Milwaukee, WI6 etid
- Cedar Rapids, IA6 etid
Lòt etid nan Boston
- Kansè nan tete111 etid
- Kansè Poumon ki pa ti selil90 etid
- Kansè (tout kalite)86 etid
- Kansè kolorektal63 etid
- Kansè Metastatik63 etid
- Kansè poumon62 etid
- Kansè ovè61 etid
- Kansè pwostat59 etid
- Depresyon52 etid
- Kansè Endomèt50 etid
- Ensifizyans kadyak44 etid
- Leksemi mieloïd egi44 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.